Corterve
10 Studies Recruiting

Clinical Trials Near Pittsburgh, PA

Find research studies actively recruiting participants near Pittsburgh. Studies are run at established research institutions including UPMC and University of Pittsburgh Medical Center.

Top Research Institutions in Pittsburgh

1

UPMC

2

University of Pittsburgh Medical Center

3

Allegheny Health Network

Recruiting Studies Near Pittsburgh

#1

Assessing Improvements in Mood and Sleep Trial

RECRUITINGNAUniversity of Pittsburgh

This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad moods, and any suicidality. Participants will complete diagnostic interviews, self-report scales, and wear an actigraphy device for the 8 weeks starting at the baseline visit.

📍 Los Angeles, California📍 Augusta, Georgia📍 Pittsburgh, Pennsylvania
#2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RECRUITINGPHASE2National Cancer Institute (NCI)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.

📍 Birmingham, Alabama📍 Phoenix, Arizona📍 Tucson, Arizona
#3

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

RECRUITINGPHASE2NSABP Foundation Inc

The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.

📍 Gainesville, Florida📍 Iowa City, Iowa📍 Kansas City, Kansas
#4

APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

RECRUITINGNAMedstar Health Research Institute

The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).

📍 Birmingham, Alabama📍 Palo Alto, California📍 Washington D.C., District of Columbia
#5

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

RECRUITINGPHASE3AstraZeneca

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

📍 Little Rock, Arkansas📍 La Jolla, California📍 Fort Myers, Florida
#6

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

RECRUITINGNANuvaira, Inc.

The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.

📍 Birmingham, Alabama📍 Jacksonville, Florida📍 Detroit, Michigan
#7

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

RECRUITINGPHASE2Pharming Technologies B.V.

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

📍 Orange, California📍 San Diego, California📍 Aurora, Colorado
#8

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

RECRUITINGPHASE3Novartis Pharmaceuticals

This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).

📍 Andalusia, Alabama📍 Huntsville, Alabama📍 Mobile, Alabama
#9

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

RECRUITINGPHASE2Shionogi

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.

📍 Irvine, California📍 Gainesville, Florida📍 Atlanta, Georgia
#10

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

RECRUITINGPHASE3Pfizer

BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone. A subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and/or pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and/or toddler (booster) doses.

📍 Birmingham, Alabama📍 Birmingham, Alabama📍 Birmingham, Alabama

Clinical Trials in Pittsburgh: FAQ

How do I find clinical trials near Pittsburgh?

Corterve aggregates all actively recruiting clinical trials near Pittsburgh, PA from the ClinicalTrials.gov database. Simply browse the listings on this page or take our free health assessment to find trials you may qualify for.

Are clinical trials in Pittsburgh free?

Yes, clinical trials are free for participants. The research sponsor covers all study-related costs. Many trials near Pittsburgh, PA also provide compensation for your time and travel expenses.

What research institutions are located in Pittsburgh?

Pittsburgh is home to several leading research institutions, including UPMC, University of Pittsburgh Medical Center, Allegheny Health Network. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to Find a Trial Near You?

Take our free 2-minute health assessment to see research studies recruiting near Pittsburgh that you may be eligible for. No insurance required.

Start Free Assessment